当地时间12月7日，本次美国血液学会（ASH）大会备受关注的“ASH老年急性髓系白血病（AML）的临床实践指南更新”专场会议顺利召开。本次会议由指南牵头专家、西尔维斯特综合癌症中心血液科主任Mikkael ...

Review of current and emerging treatments for older adults with acute myeloid leukemia, highlighting venetoclax plus hypomethylating agents and future targeted therapy combinations in routine care.

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

Guidelines recommend older adults with newly diagnosed AML should be offered antileukemic therapy over best supportive care.

TP53突变的急性髓性白血病（AML）患者预后极差，常表现为对常规化疗的抵抗和高复发风险。尽管HLA匹配的同胞供体（MSD）是异基因造血干细胞移植（allo-HCT）的首选，但仅有约30%的患者能够获得合适的MSD。在缺乏MSD的情况下，临床上面临着供体选择的困境，亟需明确 单倍体相合供体（Haplo）和匹配无关供体（MUD）在TP53突变AML患者中的移植效果。

如果患者无法耐受强化疗，可选择去甲基化药物（比如阿扎胞苷）或低剂量阿糖胞苷，并联合 Venetoclax—这是一种近年来获批的BCL-2抑制剂，能精准促使白血病细胞凋亡。更令人振奋的是，针对特定基因突变的靶向药已写入一线推荐：1）FLT3突变→FLT3抑制剂；IDH1/IDH2突变→去甲基化药物联合IDH抑制剂（比如伊沃西替尼）。

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit ...

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...

High-dose daunorubicin improved complete response rates in patients aged 60 and younger and survival in those younger than 50. Despite considerable advances during the past 20 years in the diagnostic ...